ArticleCancer medicine2023

Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor.

Naoto Takahashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.